Volume 12 Supplement 1

Melanoma Bridge 2013: Poster and Oral Presentations

Open Access

Long-term response after electrochemotherapy in patients with relapsed or refractory cutaneous melanoma

  • Nicola Mozzillo1,
  • Corrado Caracò1,
  • Ugo Marone1Email author,
  • Ester Simeone2,
  • Stefano Mori1,
  • Lucia Benedetto1,
  • Gianluca Di Monta1,
  • Maria Luisa Di Cecilia1,
  • Massimiliano Di Marzo1,
  • Gerardo Botti3 and
  • Paolo Antonio Ascierto2
Journal of Translational Medicine201412(Suppl 1):P1

https://doi.org/10.1186/1479-5876-12-S1-P1

Published: 6 May 2014

Background

Treatment of early and multiple cutaneous unresectable recurrences is a major therapeutic problem with around 80% of patients relapsing within 5 years [1]. For lesions refractory to elective treatments, electrochemotherapy (ECT) involving electroporation combined with antineoplastic drug treatment appears to be a new potential option [2]. This study was undertaken to analyze the short- and long-term responses of lesions treated with ECT with intravenous injection of bleomycin in melanoma patients with in-transit disease or distant cutaneous metastases.

Materials and methods

Between January 2007 and September 2012, 60 patients with relapsed and refractory cutaneous melanoma metastases or in-transit disease underwent 100 courses of ECT with intravenous injection of bleomycin. Response to treatment was evaluated three months after ECT. A long-lasting response was defined as no cutaneous or in-transit relapse after a minimum of six months.

Results

Three months after ECT, a complete response was observed in 29 patients (48.4%), a partial response in 23 patients (38.3%) and no change or progressive disease in 8 patients (13.3%). The objective response rate of all treated lesions was 86.6%. Thirteen patients (44.8% of complete responders) experienced a long-lasting response to ECT and were disease-free after a mean duration of follow-up of 27.5 months.

Conclusions

The favorable outcome obtained in the present study demonstrates that ECT is a reliable, and effective procedure that provides long-term benefit in terms of curative and palliative treatment for unresectable cutaneous lesions without adversely impacting the quality of life of patients [37].

Authors’ Affiliations

(1)
Unit of Surgery “Melanoma - Soft Tissues”, National Cancer Institute
(2)
Unit of Medical Oncology, National Cancer Institute
(3)
Unit of Pathology, National Cancer Institute

References

  1. Leon P, Daly J, Synnestvedt M, Schultz DJ, Elder DE, Clark WH: The prognostic implications of microscopic satellites in patients withclinical Stage I melanoma. ArchSurg. 1991, 126: 1461-68.Google Scholar
  2. Marty M, Garbay JM, Gehl J: Electrochemotherapy an easy, highly effective and safe treatment of cutaneous and subcutaneous metastases: results of ESOPE (European Standard Operating Procedures of Electrochemotherapy) study. Eur J Cancer. 2006, 4: 3-13.View ArticleGoogle Scholar
  3. Sersa G, Miklavcic D, Cemazar M, Rudolf Z, Pucihar G, Snoj M: Electrochemotherapy in treatment of tumors. Eur J SurgOncol. 2007, 34: 232-40.View ArticleGoogle Scholar
  4. Quaglino P, Mortera C, Osella-Abate S: Electrochemotherapy with intravenous bleomycin in the local treatment of skin melanoma metastases. Ann Surg Oncol. 2008, 15: 2215-22. 10.1245/s10434-008-9976-0.View ArticlePubMedGoogle Scholar
  5. Sersa G, Stabuc B, Cemazar M, Miklavcic D, Rudolf Z: Electrochemotherapy with cisplatin: systemic antitumor effectiveness of cisplatin can be potentiated locally by the application of electric pulses in the treatment of malignant melanoma skin metastases. Melanoma Res. 2000, 10: 381-85. 10.1097/00008390-200008000-00010.View ArticlePubMedGoogle Scholar
  6. Kaehler KC, Egberts F, Hauschild A: Electrochemotherapy in symptomatic melanoma skin metastases: intraindividual comparison with conventional surgery. Dermatol Surg. 2010, 36: 1200-02. 10.1111/j.1524-4725.2010.01608.x.View ArticlePubMedGoogle Scholar
  7. Mozzillo N, Caracò C, Mori S: Use of neoadjuvantelectrochemotherapy to treat a large metastatic lesion of the cheek in a patient with melanoma. J Transl Med. 2012, 10: 131-10.1186/1479-5876-10-131.PubMed CentralView ArticlePubMedGoogle Scholar

Copyright

© Nicola et al; licensee BioMed Central Ltd. 2014

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Advertisement